Phibro Animal Health’s (NASDAQ:PAHC) Q1 CY2026: Beats On Revenue

Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 10.3% year on year to $383.5 million. On the other hand, the company’s full-year revenue guidance of $1.48 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.76 per share was 6.5% above analysts’ consensus estimates.

Is now the time to buy Phibro Animal Health? Find out by accessing our full research report, it’s free.

“Phibro delivered a strong third quarter, with net sales increasing 10% to $383.5 million and adjusted EBITDA rising 11% to $60.8 million,” said Jack Bendheim, Chairman, President and Chief Executive Officer of Phibro Animal Health Corporation.

Company Overview

With a portfolio of approximately 800 product lines serving farmers and veterinarians in 90 countries, Phibro Animal Health (NASDAQ:PAHC) develops, manufactures, and markets health products for livestock and companion animals, including antibacterials, vaccines, nutritional supplements, and mineral additives.

Revenue Growth

A company’s long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last five years, Phibro Animal Health grew its sales at a solid 13.4% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Phibro Animal Health’s annualized revenue growth of 22.5% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated.

This quarter, Phibro Animal Health reported year-on-year revenue growth of 10.3%, and its $383.5 million of revenue exceeded Wall Street’s estimates by 8%.

Looking ahead, sell-side analysts expect revenue to grow 1.1% over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and indicates its products and services will see some demand headwinds.

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.

Adjusted Operating Margin

Phibro Animal Health has done a decent job managing its cost base over the last five years. The company has produced an average adjusted operating margin of 10%, higher than the broader healthcare sector.

Analyzing the trend in its profitability, Phibro Animal Health’s adjusted operating margin rose by 3.6 percentage points over the last five years, as its sales growth gave it operating leverage. The company’s two-year trajectory shows its performance was mostly driven by its recent improvements.

In Q1, Phibro Animal Health generated an adjusted operating margin profit margin of 11.7%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.

Phibro Animal Health’s EPS grew at 21.2% compounded annual growth rate over the last five years, higher than its 13.4% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.

We can take a deeper look into Phibro Animal Health’s earnings to better understand the drivers of its performance. As we mentioned earlier, Phibro Animal Health’s adjusted operating margin was flat this quarter but expanded by 3.6 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q1, Phibro Animal Health reported adjusted EPS of $0.76, up from $0.63 in the same quarter last year. This print beat analysts’ estimates by 6.5%. Over the next 12 months, Wall Street expects Phibro Animal Health’s full-year EPS of $2.93 to grow 10.8%.

Key Takeaways from Phibro Animal Health’s Q1 Results

We were impressed by how significantly Phibro Animal Health blew past analysts’ revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. On the other hand, its full-year revenue guidance slightly missed. Overall, this print had some key positives. The market seemed to be hoping for more, and the stock traded down 3.6% to $56.47 immediately following the results.

Is Phibro Animal Health an attractive investment opportunity right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).